In Section A, contributors will receive diverse doses and schedules of oral ABBV-744 pill to determine Risk-free dosing program. Extra members might be enrolled at the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In Phase C, https://gregoryqhsdo.actoblog.com/32586688/the-basic-principles-of-abbv-744-in-acute-myeloid-leukemia-aml